Worcester-based Biovest International Inc. said its BiovaxID cancer treatment therapy kept 40 percent of patients disease free for between 40 and 70 months during six years of clinical trials.
The treatment is for non-Hodgkin’s Lymphoma, and is what Biovest calls “a personalized, patient-specific vaccine designed to stimulate the patient’s own immune system to recognize and destroy” residual cancer cells after chemotherapy.
The Biovax Phase 3 clinical trial is being conducted at 14 oncology centers in the U.S. and at eight sites in Russia.
The company is asking the U.S. Food and Drug Administration and the European Medicines Agency for accelerated approval, and plans to submit the treatment to those agencies in mid-2008. The company said BiovaxID could be commercially available in early 2009.
Biovest is a subsidiary of Accentia Biopharmaceuticals Inc. of Florida.
